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Abstract Transfer of naked plasmid with insulin precursor
DNA into skeletal muscle of streptozotocin (STZ)-induced
diabetic mice through electroporation and detection of gene
expression is described. Four different human insulin precursor
DNA fragments were inserted into pcDNA3.1(3), downstream
of a CMV promoter. Three of them, with a secretion signal
sequence, succeeded in lowering blood glucose at a range of 30^
50% in STZ diabetic mice. The other, with a synthetic DNA
fragment encoding human proinsulin, failed. The mortality rate
of very seriously STZ diabetic mice was reduced significantly by
the treatment. The circulating insulin-like protein (mouse insulin,
human proinsulin, or intermediates during conversion of proin-
sulin to insulin) level in the blood of less seriously STZ diabetic
mice treated with the human preproinsulin gene with an intron
was about 15^23 WU/ml, while that of STZ diabetic mice treated
with empty vector was only about 6 WU/ml and that of normal
mice was about 18 WU/ml. Transcription of the three human
insulin precursor DNAs in mouse skeletal muscle was also
detected by RT-PCR. The human preproinsulin gene with the
intron showed a slightly higher potency in reducing blood glucose
of mildly diabetic mice. These studies indicate that the skeletal
muscle transferred with appropriate preproinsulin DNA by
electroporation in vivo can secrete insulin-like protein resulting
in reduction of blood glucose, and a basal blood insulin level can
be achieved for at least 1 month. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
In most cases, genes are transferred by infectivity of viral
particles in gene therapy. Retroviruses can achieve e⁄cient
integration, but with the disadvantages of low titer, instability
of the viral vector and requirement for target cells in division.
Adenoviruses can provide more e⁄cient gene transfer, but
with limitations such as the risk of transgene dissemination
outside the tumor [1]. Lipofection with cationic liposomes
associated with anionic plasmid DNA has been shown to
deliver foreign genes e⁄ciently into cells both in vitro and
in vivo [2,3]. However, endocytosed plasmid DNA is liable
to be digested in the lysosomes, and cationic liposomes have
cytotoxicity [4]. Among the methods of gene transfer, electro-
poration can e⁄ciently introduce plasmid into skin [5], chick
embryo [6], liver [7], and muscle [8^11]. Intramuscular electro-
transfer can strongly increase reporter and therapeutic gene
expression by several orders of magnitude as compared to
naked DNA [8^10] and the expression can last for up to
9 months [8]. Plasmid gene transfer by electroporation has
several advantages over transfer using viral vectors: a large
quantity of highly puri¢ed plasmid DNA can be easily and
inexpensively prepared; plasmid vector can carry larger genes;
a mixture of two or more di¡erent plasmid constructs can be
co-transferred into muscle by electroporation [11]. Plasmid
DNA is an unintegrated form, but can express in myo¢bers
[12]. Compared with other gene transfer methods, transferring
genes into muscle is simple, safe and inexpensive [8^13], and
may have much higher potential in clinical applications.
Insulin-dependent diabetes mellitus (IDDM) is caused by a
shortage of insulin secretion. Since insulin-producing L cells
are destroyed to a certain degree, gene therapy for IDDM has
to ¢nd a way to transfer the insulin gene into an ectopic
organ. The exocrine glands of the gastrointestinal system,
such as the liver, have been frequently used as target organs
[14,15]. Bartlett et al. [16,17] proved that skeletal muscle could
secrete insulin-like protein after direct injection of naked in-
sulin precursor DNA. In our investigation, to undertake a
simple approach to gene therapy for diabetes and to compare
the treatment e¡ects of di¡erent insulin precursor DNA con-
structs, skeletal muscle was selected as the target organ. Four
expression plasmids with di¡erent insulin precursor DNAs
were constructed and transferred into skeletal muscle of strep-
tozotocin (STZ) diabetic mice by electroporation in vivo. The
e¡ects of gene therapy on STZ diabetic mice are reported.
2. Materials and methods
2.1. Materials
The human preproinsulin gene in pBAT16.hinsG1.M2 was kindly
provided by Dr. Michael S. German, University of California at San
Francisco, CA, USA [18]. There is a furin recognition site mutation
between the C peptide and the A chain. The gene has an intron within
the sequence of the C peptide and is 1119 bp large. The human
preproinsulin cDNA in pT7hPPI-1 was kindly provided by Dr. Del-
phine Mitanchez, Institut Cochin de Ge¤ne¤tique Mole¤culaire, Paris,
France (originally provided by Dr. Kevin Docherty, Department of
Molecular and Cell Biology, Aberdeen, UK). The pBCA containing
synthetic DNA encoding human proinsulin was a gift from Dr. Tong-
jian Shen of the Institute of Biophysics, Academia Sinica (originally
provided by Dr. Ray Wu [19]). Expression vector pcDNA3.1(3) was
purchased from Invitrogen. Restriction enzymes, T4 DNA ligase, all
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components required for production of cDNA and RT-PCR analysis
were purchased from Promega. STZ was purchased from Sigma.
2.2. Construction of a mutant human preproinsulin cDNA
The human native preproinsulin cDNA in pT7hPPI-1 was mutated
by PCR to make a furin recognition site between the C peptide and
the A chain. The 5P-primer IN5, 5P-ccagaattcatggccctgtggatg-3P, and
mutant primer INBC, 5P-tctgccgggatccctccagggc-3P, were used to get
the upstream fragment. The complementary mutant primer INA,
5P-gagggatcccggcagaagcgtg-3P, and 3P-primer IN3, 5P-actaagcttctagttg-
cagtagttctccag-3P, were used to get the downstream fragment. The
mutant preproinsulin cDNA was then obtained by another PCR
with the above two fragments as template and with primers IN5
and IN3. The mutant sequence between the C peptide and the A chain
is the same as that of the mutant human preproinsulin gene in pBA-
T16.hinsG1.M2. The mutation was con¢rmed by DNA sequencing.
2.3. Construction of the eukaryocyte expression plasmids
All plasmids were constructed by routine molecular cloning tech-
niques [20]. The vector pcDNA3.1(3) contains a CMV promoter. The
human preproinsulin gene in pBAT16.hinsG1.M2 was ampli¢ed by
PCR with primers IN5 and IN3 and introduced into pcDNA3.1(3) to
construct pCMV-IN. Likewise, the human preproinsulin cDNA in
pT7hPPI-1 was introduced into pcDNA3.1(3) to get pCMV-IN-
cDNA and the mutant human proinsulin cDNA was inserted to get
pCMV-INcDNAm. All above foreign DNA fragments were inserted
into the multi-cloning site of pcDNA3.1(3) between the EcoRI and
HindIII sites. The pBCA was digested by EcoRI and BamHI and the
synthetic human proinsulin DNA was isolated from agarose gel and
cloned into the multi-cloning site of pcDNA3.1(3) to get pCMV-
proIN. All above human insulin precursor genes are shown in Fig.
1 and controlled by the CMV promoter.
2.4. Treatment of animals
Male C57BL/6J mice (from the medical experimental animal center,
Peking University), 6^8 weeks, weight about 18^20 g, were injected
intraperitoneally with a dose of 40 mg STZ/kg body weight on ¢ve
consecutive days. STZ was dissolved in a 10 mmol/l sodium citrate
solution with 0.9% NaCl, pH 4.5, immediately before administration.
The mice with blood glucose levels in the range of 15^30 mmol/l were
selected and used 20^30 days after STZ treatment. All mice were fed
at room temperature with su⁄cient water and food.
2.5. DNA injection and electroporation
100 Wg of DNA in 100 Wl of 0.9% NaCl was injected into two back
sural muscles of each mouse. Transcutaneous electric pulses were
applied by two stainless steel needle electrodes placed about 5 mm
apart on each side of the muscle just after DNA injection. The deliv-
ery of pulse was 40 ms and repeated 10 times. The electric ¢eld
strength was 200 v/cm, frequency 1 Hz. There were at least ¢ve
mice in each experimental group.
2.6. Blood glucose and serum insulin-like protein assays
Blood samples collected from the tail were used to measure blood
glucose directly with a Glucotrend monitor and Glucotrend Glucose
test strips (Roche Diagnostics, detection range: 0.6^33.3 mmol/l).
Blood samples for insulin assay were collected from bulbus oculi,
and centrifuged at 8000Ug for 10 min. Serum was kept at 320‡C
until serum insulin-like protein was measured by RIA. Rabbit poly-
clonal anti-human insulin antibodies, which have a cross-reactivity of
40^50% to mouse insulin (Navy R.I.A. Technique Center, Beijing),
were used in the assay. All samples were collected at 15.00^17.00 h.
2.7. RT-PCR assay of human insulin precursor DNA transcription in
severely diabetic mouse muscle
Three weeks after injection of human insulin precursor DNA in
severely diabetic mouse muscle, about 100 mg of injected muscle tis-
sue was dissected. Total RNA of the muscle sample was prepared by
acid guanidinium thiocyanate^phenol^chloroform extraction and
treated with DNase I to eliminate contaminated genomic DNA.
Speci¢c preproinsulin gene primers IN5 and IN3, and L-actin prim-
ers 5P-gtggggcgcccaggcacct-3P and 5P-cttccttaatgtcacgcacgattg-3P were
used for RT-PCR analysis. The PCR was done as 94‡C for 1 min,
55‡C for 1 min, 72‡C for 1 min, 30 cycles, followed by an extension of
8 min at 72‡C. The PCR products were analyzed by 1.5% agarose gel
electrophoresis. The lengths of the expected PCR products were 340
bp for preproinsulin and 545 bp for L-actin.
2.8. Statistics
Data are given as mean þ S.E.M. Statistical signi¢cance of di¡er-
ences between groups was determined by Student’s t-test. The level of
signi¢cance is P6 0.05.
3. Results
3.1. Reduction of blood glucose in insulin precursor
DNA-treated STZ diabetic mice
Human insulin precursor DNA expression constructs under
the control of the CMV promoter were prepared by molecular
cloning techniques and the gene structures are demonstrated
in Fig. 1. To determine the e¡ect of transfer of naked plas-
mids with insulin precursor DNA into muscle, the blood glu-
cose of STZ diabetic mice was measured. Blood glucose pro-
Fig. 1. Structure of four human insulin precursor DNAs. P, secre-
tion signal sequence; B, insulin B chain; C, C peptide; A, insulin A
chain; IVS, intervening sequence or intron. There is a furin protease
site between the C peptide and the A chain in INcDNAm and IN.
Four human insulin precursor DNAs were cloned into
pcDNA3.1(3) under the control of a CMV promoter.
Fig. 2. The e¡ect of various plasmids with di¡erent insulin precur-
sor DNAs on the blood glucose of severely diabetic mice. Mice
with blood glucose levels of 25^30 mmol/l were selected and used
20^30 days after STZ treatment. Various plasmids were injected.
pcDNA3.1(3) was used as a control. 100 Wg DNA for each mouse
was injected and electroporated. Blood samples from the tail were
obtained 7, 14, 21, or 28 days later, and glucose contents were de-
termined on a Glucotrend monitor with Glucotrend glucose test
strips. All mice were fed at room temperature with su⁄cient water
and food. Blood glucose levels in healthy non-STZ-treated mice
were 5.89 þ 0.29 mmol/l ; n = 5; *P6 0.05.
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¢les of 28 days were established at 7 day intervals. The se-
verely diabetic mice with blood glucose levels of 25^30 mmol/l
were selected, and four types of plasmids were transferred
separately. Three of them, pCMV-IN, pCMV-INcDNA and
pCMV-INcDNAm, could reduce about 30% of blood glucose
at the most e⁄cient. pCMV-proIN, however, had only a small
e¡ect of abating blood glucose (Fig. 2). When the illness of
STZ diabetic mice was less serious at about 20 mmol/l blood
glucose level, the blood glucose could be reduced to 50% by
pCMV-IN (Fig. 3).
3.2. Evaluation of serum insulin-like protein in mildly diabetic
mice treated with pCMV-IN
The serum insulin-like protein was measured by RIA with
human insulin polyclonal antibodies. Normal mice and STZ
diabetic mice transferred with pcDNA3.1(3) were used as
controls. The insulin-like protein level in mildly diabetic
mice treated with pCMV-IN was much higher (15^23 WU/
ml) than with pcDNA3.1(3) (about 6 WU/ml) (Fig. 4), and
was nearly equal to that of normal mice (about 18 WU/ml).
3.3. RT-PCR assay of human insulin precursor mRNA in
severely diabetic mouse skeletal muscle
Twenty-one days after mice were injected with pCMV-IN,
pCMV-INcDNA or pCMV-INcDNAm, the presence of insu-
lin precursor mRNA transcribed in the muscle tissue was
determined by RT-PCR. The insulin precursor mRNA was
detected in muscle tissue injected with human insulin precur-
sor DNA, but not with empty vector pcDNA3.1(3) (Fig. 5).
3.4. Mortality rate decrease for very seriously STZ diabetic
mice with insulin precursor DNA treatment
When mice were treated with STZ at an overdose of 50 mg/
kg body weight on ¢ve consecutive days, the mice would have
a very serious diabetes after 3 weeks, and most of them would
die within the next 4 weeks. If injected with either pCMV-IN
or pCMV-INcDNA, the mortality rates were clearly de-
creased (Table 1), but not with pCMV-proIN.
4. Discussion
Muscle as the target tissue for foreign gene transfer has
been demonstrated to result in transgene expression and ther-
apeutic responses [8^12,16,17,21,22]. Muscle may be particu-
larly appropriate to take up and express foreign DNA because
of its multinucleated cell, sarcoplasmic reticulum, and trans-
verse tubule system, which contains extracellular £uid and
penetrates deep into the muscle cell [12]. The DNA may enter
damaged muscle cells, which then recover [12]. Muscle is use-
ful in delivering cytokines, growth factors, and other serum
proteins by intramuscular DNA injection [11]. That the ec-
topic insulin-like protein was expressed in skeletal muscle in
the present investigation provides another line of evidence.
Gene transfer is often one of the limiting steps in gene
therapy. Electroporation provides a more e⁄cient method of
gene transfer in vivo [1,7^11]. Electroporation is a technique
involving the application of short-duration, high-intensity
electric pulses to a cell or tissue [23]. The electrical stimulus
causes membrane destabilization and subsequent formation of
nanometer-sized pores. In this permeabilized state, the mem-
Fig. 3. The e¡ect of various plasmids with insulin precursor DNAs
on the blood glucose of mildly diabetic mice. Mice with blood glu-
cose about 20 mmol/l were selected for injection of various plas-
mids. pcDNA3.1(3) was used as control. 100 Wg DNA for each
mouse was injected and electroporated. Blood samples from the tail
were obtained 7, 14, 21, or 28 days later, and glucose contents were
determined on a Glucotrend monitor with Glucotrend glucose test
strips. All mice were fed at room temperature with su⁄cient water
and food. Blood glucose levels in healthy non-STZ-treated mice
were 5.89 þ 0.29 mmol/l; n = 6; *P6 0.05.
Table 1
The e¡ect of human insulin precursor DNAs on the mortality rate of very seriously STZ diabetic mice
Plasmid with
insulin DNA
Beginning number of
STZ diabetic mice
Number of deaths in STZ
diabetic mice in 4 weeks
Mortality rate of STZ
diabetic mice (%)
pcDNA3.1(3) 28 24 85.7
pCMV-proIN 20 16 80.0
pCMV-IN 19 4 21.1
pCMV-INcDNA 19 5 26.3
The blood glucose of very seriously STZ diabetic mice was over 33 mmol/l.
Fig. 4. The e¡ect of pCMV-IN on serum insulin-like protein of
mildly diabetic mice. Blood samples for insulin assay were collected
from bulbus oculi, and centrifuged at 8000Ug for 10 min. Serum
insulin-like protein (mouse insulin, human proinsulin, and some pos-
sible intermediates during conversion from proinsulin to insulin)
was measured by RIA with human insulin polyclonal antibodies.
The serum insulin of normal mice is 18.0 þ 3.8 WU/ml; n = 5;
*P6 0.05.
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brane can allow passage of macromolecules into the cell [1].
Electroporation has been used to transfer plasmid DNA in
vivo to many kinds of organs [5,7^11]. Electroporation was
equally e⁄cient in transferring genes to both regenerating and
normal muscle [11]. Mir et al. reported an e⁄cient method for
DNA transfer into muscle ¢bers, which consists of plasmid
DNA intramuscular injection, followed by delivery of low-
¢eld-strength, long-duration, square-wave electric pulses
through external or invasive electrodes [8]. The expression
of Photinus pyralis peroxisomal luciferase could last for
more than 9 months in mice [8]. A similar method was used
in our study.
Four di¡erent human insulin precursor DNAs were used in
our study. Among these insulin precursor DNAs, the syn-
thetic DNA encoding human proinsulin without signal pep-
tide in pCMV-proIN could not e⁄ciently reduce the blood
glucose of STZ diabetic mice (Fig. 2). pCMV-proIN also
showed no e¡ect on the reduction of the mortality rate of
very seriously diabetic mice as compared with pCMV-IN
and pCMV-INcDNA, which have the signal peptide (Table
1). This indicates that the signal peptide is probably necessary
for the insulin precursor to be successfully secreted from the
muscle cells. pCMV-IN with the human preproinsulin gene
could reduce the blood glucose of mildly diabetic mice more
e⁄ciently than pCMV-INcDNAm with human preproinsulin
cDNA (Fig. 3). The di¡erence between the human preproin-
sulin gene and human preproinsulin cDNA is that there is an
intron in the preproinsulin gene. The intron may enhance the
transcription of the preproinsulin gene in the muscle cell. This
suggests that using preproinsulin genomic DNA may be better
than using preproinsulin cDNA in gene therapy for diabetes.
In pancreatic L cells, proinsulin is processed into mature
insulin by proteases, PC2 and PC3 [24]. PC3 cleaves at the
Arg-Arg sequence in the B chain and C peptide junction. PC2
cleaves at the Lys-Arg sequence in the C peptide and A chain
junction [25]. Normally this maturation process from native
proinsulin does not occur in any non-endocrine cell through
the lack of the speci¢c proconvertases. One possibility to over-
come this limitation in non-endocrine cells is to engineer some
speci¢c sequence for processing. The sequence at the AC junc-
tion can be changed to give a site that can be cleaved by furin,
a ubiquitous endoprotease [26], to allow proinsulin being pro-
cessed to mature insulin in non-endocrine cells [14,27]. The
Arg-X-Lys/Arg-Arg sequence is a signal for furin cleavage. In
our study, the human preproinsulin gene in pCMV-IN has a
native sequence Lys-X-Arg-Arg for the BC junction and a
mutant sequence Arg-X-Lys-Arg for the AC junction. Human
insulin was reported to have almost equal potency in stimu-
lation of glucose oxidation activity as compared with mouse
insulin in the rat adipocyte assay, while proinsulin only
showed 2^3% of insulin activity [28]. The blood glucose of
transgenic STZ diabetic mice did show a decrease (Figs. 2
and 3), but never dropped to the normal level in spite of their
nearly normal serum insulin-like protein level (Fig. 4). The
pCMV-INcDNA construct gave a similar potency in reducing
blood glucose as both pCMV-IN and pCMV-INcDNAm with
the furin cleaving site (Fig. 2). This indicates that the proin-
sulin expressed in muscle cells was not e⁄ciently processed
into highly active insulin. The furin may be not abundant in
skeletal muscle cells. The serum insulin-like protein we de-
tected may include mouse insulin, human proinsulin, and pos-
sibly some intermediates during conversion of proinsulin to
insulin. Successful transcription of the preproinsulin genes in
muscle tissues has also been identi¢ed by RT-PCR analysis
(Fig. 5).
The data analysis for glucose level reduction, mortality rate
reduction, secretion of insulin-like protein and RT-PCR re-
sults indicates that the skeletal muscle is an excellent target
organ for ectopic insulin precursor gene expression. Although
we are using constitutive secretion to produce insulin-like pro-
tein rather than regulated secretion, none of the mice with
su⁄cient water and food su¡ered from hypoglycemia in our
experiment. The Diabetes Control and Complications Trial
suggested that tight control of glycemia could prevent or ap-
preciably reduce the incidence of long-term complications as-
sociated with IDDM [29]. However, relatively few patients are
capable of complying with the strict regimens required for
achieving euglycemia with open loop insulin treatment [13].
Using muscle as a target organ for gene therapy of diabetes
may protect and reduce complications by keeping a basal
insulin level in patients. It may be relatively a safe and simple
approach of gene therapy for diabetes. Our data also indicate
that the transgenic muscle tissue can keep expressing insulin-
like protein for more than 1 month. This is especially good as
patients would receive only one injection in more than
1 month instead of three daily injections of insulin protein.
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